However, adverse events resulting from PegIFN/RBV treatment continued to be a major issue requiring close monitoring, dose reductions, and even early discontinuation in the treatment of chronic hepatitis C[16] and led to a huge gap between high clinical efficacy (80%) and little community effectiveness (13%) in Taiwan.[7] Nevertheless, due to a relatively favorable conformation of HCV genotypes and IL28B SNPs,[17,18] carefully chosen patient groups according to genotype,[19] fibrosis stage,[20] and IL28B allele[21] boosted efficacy, ameliorated adverse events, and reduced medical expenses. The gene discussed is IFNL3; the disease is chronic hepatitis C virus infection.